

## LIST OF FIGURES

FIGURE	Page No.
1. Site of action of some antifungal compounds used clinically are italicized.....	11
2. Site of action of some clinically useful ergosterol synthesis inhibitors. ....	14
3(a). Structure of few antifungal used in current day therapy. ....	17
3(b). Structure of few antifungal used in current day therapy. ....	18
4. Corey-Pauling space filling model of amphotericin B. ....	20
5. Structure of amphotericin B cholesterol pore. ....	21
6. Structure of cholesterol (a) and ergosterol (b). ....	23
7. Structure of phospholipid . ....	28
8. Self-aggregation of polar lipid molecules. ....	30
9. Diagram of fat and water soluble agents encapsulated liposome ....	33
10. Theory for why liposomal amphotericin B is less toxic than conventional amphotericin B. ....	38
11. Schematic representation of four major liposome types. ....	42
12. Putative structure of Abelect. ....	46
13. Structure features of Amphocil. ....	49
14. Schematic structure of Amphotericin B small unilamellar vesicle (AmBisome). ....	52
15. Structure of $\beta$ -Cyclodextrin derivatives. ....	57
16. Schematic illustration of mechanism of drug – cyclodextrin inclusion complexation. ....	60
17 (a). Flow chart for the formation of inclusion complex of amphotericinB with $\beta$ -cyclodextrin. ....	75
17(b). Flow chart for the preparation of liposomes. ....	76
18. Roll compactor (M/s. GPMC, Mumbai)used for the formation of Inclusion complexes. ....	88
19. DSC study of interaction of $\beta$ -CD and drug (AmB) ....	91
20(a-d). Electron micrograph of proliposome mixtures. ....	117-118
21. $^{31}\text{P}$ -NMR scans obtained for mixtures containing different proportions of EPC ethanol water (buffer). ....	120
22. Typical $^{31}\text{P}$ -NMR scans obtained for mixtures containing different proportions of DOPC ethanol water (buffer). ....	121
23(a-d). Electron micrograph of EPC and DOPC liposome entrapped (AmB-HPBCD/SBEBCD). ....	124-125
24. Standard curve of amphotericin B at 405 nm. ....	123
25(a-d). Size distribution of EPC and DOPC liposomes derived from proliposome mixtures containing lipid : ethanol : water(buffer). ....	126-129
26(a-b). Percentage AmB released from various batches of EPC liposome entrapped AmB-HPBCD/SBEBCD inclusion complexes. ....	130-132
27(a-b). Percentage AmB released from various batches of DOPC liposome entrapped AmB-HPBCD/SBEBCD inclusion complexes. ....	133-134
28. Stability of EPC : Chol : DOPC (AmB-HPBCD) liposomes in terms of AmB loss at different pHs at 37 <sup>0</sup> C. ....	136
29. Stability of EPC : Chol : DCP (AmB – SBEBCD) liposomes in terms of AmB loss at different pHs at 37 <sup>0</sup> C. ....	137
30. Stability of DOPC : Chol : DCP (AmB – HPBCD) liposomes in terms of AmB loss at different pHs at 37 <sup>0</sup> C. ....	138
31. Stability of DOPC : Chol : DOPC (AmB-SBEBCD) liposomes in terms of AmB loss different pHs at 37 <sup>0</sup> C. ....	139
32. Degradation curve for AmB in product EPC : Chol : DCP (AmB – HPBCD) liposome . ....	146
33. Arrhenius plot for AmB in product EPC : Chol : DCP (AmB – HPBCD) liposome. ....	147

34.	Degradation curve for AmB in product EPC : Chol : DCP (AmB – SBEB CD) liposomes.	148
35.	Arrhenious plot for AmB in product EPC : Chol : DCP (AmB – SBEB CD) liposomes.	149
36.	Degradation curve for AmB in plain drug (dry)	150
37.	Arrhenious plot for AmB in plain drug (dry).	151
38.	Degradation curve for AmB in product DOPC : Chol :DCP (AmB – HPBCD) liposomes .	154
39.	Arrhenious plot for AmB in product DOPC : Choi : DCP (AmB – HPBCD) liposomes.	155
40.	Degradation curve for AmB in product DOPC : Chol : DCP (AmB – SBEB CD) liposomes.	156
41.	Arrhenious Plot for AmB in product DOPC : CHOL : DCP (AmB – SBEB CD) liposomes .	157
42.	Erythrocyte lysis caused by amphotericinB when delivered through AmB <sub>DOC</sub>	158
43.	Erythrocyte lysis caused by amphotericin B when delivered through EPC : Chol : DCP (AmB – HPBCD) liposomes.	159
44.	Erythrocyte lysis caused by amphotericin B when delivered through EPC : chol : DCP (AmB – SBEB CD) liposomes.	160
45.	Erythrocyte lysis caused by amphotericin B when delivered through DOPC : Chol : DCP (AmB – HPBCD) liposomes.	161
46.	Erythrocyte lysis caused by amphotericin B when delivered through DOPC : Chol : DCP (AmB – SBEB CD) liposomes.	162
47.	Changes in serum creatinine in Balb/C treated with AmB <sub>DOC</sub> or different PBLV formulations.	163
48.	Survival of infected Balb/C mice given different AmB therapy under various conditions of treatment.	168
49(a-d).	Tissue distribution of amphotericinB in normal and <u>A. fumigatus</u> infected Balb/c mice after I.V. administration of 2mg/kg (AmB <sub>DOC</sub> ).	179-182
50(a-d).	Tissue distribution of amphotericinB in normal and <u>A. fumigatus</u> infected Balb/c mice after I.V. administration of 12mg/kg EPC : Chol : DCP liposome entrapped (AmB-SBEB CD).	186-189
51(a-d).	Tissue distribution of amphotericinB in normal and <u>A. fumigatus</u> infected Balb/c mice after I.V. administration of 12mg/kg EPC : Chol : DCP liposome entrapped (AmB-HPBCD).	190-193
52(a-d).	Tissue distribution of amphotericinB in normal and <u>A. fumigatus</u> infected Balb/c mice after I.V. administration of 12mg/kg DOPC : Chol : DCP liposome entrapped (AmB-HPBCD).	194-197
53(a-d).	Tissue distribution of amphotericinB in normal and <u>A. fumigatus</u> infected Balb/c mice after I.V. administration of 12mg/kg DOPC : Chol : DCP liposome entrapped (AmB-SBEB CD).	198-201
54.	Plasma AmB concentration –Vs- time curve following the administration of different AmB formulations.	207
55.	Plasma AmB concentration –Vs- time curve following the administration of AmB <sub>DOC</sub> with different lipid doses.	208
56.	Plasma AmB concentration –Vs- time curve following the administration of DOPC liposome entrapped AmB-HPBCD inclusion complex with different lipid doses.	209
57.	Plasma AmB concentration –Vs- time curve following the administration of DOPC liposome entrapped AmB – SBEB CD inclusion complex with different lipid doses.	210
58.	Plasma AmB concentration –Vs- time curve following the administration of EPC liposome entrapped AmB -HPBCD inclusion complex with different lipid doses.	211
59.	Plasma AmB concentration -Vs - time curve following the administration of EPC liposome entrapped AmB SBEB CD inclusion complex with different lipid doses.	212



## ACKNOWLEDGEMENTS

Many individuals have been instrumental in the completion of this work. I would like to thank each of these for their contributions to both this project and to my progress over the last several years.

I am deeply indebted to **Dr. S.R.Naik, M.Sc., Ph.D., and F.R.C.S.** for his excellent guidance, keen interest and critical appreciation throughout the course of this work. I also wish to state my sincere gratitude for his invaluable help rendered during the preparation of the thesis.

I am grateful to the Managing Director, Hindustan Antibiotics Limited for granting permission to conduct this research work at Research and Development Division.

Several individuals have been indispensable to my progress and survival throughout this project. I would like to thank Mr. S.S. Karkhanis, Dr. N. R. Chatterjee, Dr.K.P.Jadhav, and Mr.J.N.Dhule for representing what is best in the process of scientific inquiry by always having the time and interest in discussing experimental results and their implications with me. I would also thank to Mrs. Geeta Iyer for their help in completing this work. I would also like to thank Mr. Khape and Mrs. Nagarkar (Library of Bioinformatics, DIC, University of Pune) for their kind support during the reference work. I thank all of them also for exemplifying the qualities that truest and best in both colleagues and friends.

I sincerely acknowledge with regards the efforts made by Dr. Vinod Bihari, Deputy Director & Head Division of Fermentation technology, Central Drug Research Institute, Lucknow for arranging complete references of different  $\beta$ -cyclodextrin derivatives and Director, National Chemical Laboratory, Pune for granting kind permission to carrying out